British Columbia Cancer Agency clinical trial pipeline

7 trials changed in the last 30 days: 0 stopped, 3 with notable changes, 4 with minor changes only.

1. Notable

   CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With…CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease

   Primary and study completion pushed from Dec 31, 2026 to Dec 31, 2027

   British Columbia Cancer Agency·Not applicable· NCT05257967· Registry history of NCT05257967 on ClinicalTrials.gov (opens the registry)

   Oct 19, 2026

2. Notable

   CLIC-2201 · Relapsed/Refractory B Cell Malignancies

   Primary completion pushed from Aug 1, 2026 to Aug 1, 2027

   Also in this update: Study completion pushed from Aug 1, 2027 to Aug 1, 2028

   British Columbia Cancer Agency·Phase 1· NCT06208735· Registry history of NCT06208735 on ClinicalTrials.gov (opens the registry)

   Oct 14, 2026

3. Notable

   Stereotactic Ablative Body Radiotherapy (SABR) for Oligometastases

   Primary completion date changed from estimate of Dec 2025 to Aug 2026

   Also in this update: Study completion pushed from Jul 2026 to Jul 2027

   British Columbia Cancer Agency·Not applicable· NCT02933242· Registry history of NCT02933242 on ClinicalTrials.gov (opens the registry)

   Oct 1, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.